JOHANNESBURG, Feb 25 (Reuters) - South African medical schemes may no longer need to step in to subsidise COVID-19 vaccines for the wider population after the government allocated significant funds for the vaccine rollout, executives told Reuters on Thursday.
Medical schemes, funds that pool member contributions to cover healthcare costs, have been in talks with the government over funding vaccines for those without access to private health cover as well as their own members. at least 9 billion rand ($608.28 million) set aside to cover vaccine rollout in the annual budget on Wednesday may mean such an arrangement may not be needed, executives from two of the country's biggest schemes said on Thursday. would have the effect of reducing the overall cost to the medical schemes of the vaccination programme.
"It seems that the (budget) amount allocated is sufficient to fund the vaccine for public sector patients," said Adrian Gore, chief executive of insurer Discovery (JO: DSBPp ) DSYJ.J , which administers the country's largest scheme.
He added schemes and other private providers would still need to cover their own members or clients.
Around 7 million people are covered by medical schemes - less than a quarter of the 40 million people South Africa wants to vaccinate.
The country administered the first doses of the Johnson & Johnson (NYSE: JNJ )'s JNJ.N shot last week.
"I think the government is looking at this and saying this is our role," said Damian McHugh, executive head of sales and marketing at Momentum Health Solutions, another large scheme administrator.
He agreed that the budget figure suggested schemes may not need to help pay for the initial vaccination phase for non-members, though it did not entirely negate the subsidy discussion.
This would depend on which vaccines were procured, he continued, while schemes may still need to contribute in future if booster shots or fresh rounds of vaccination are needed. ($1 = 14.7958 rand)
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.